SRPT

Sarepta Therapeutics, Inc. (SRPT) | Rumor.io

Sarepta Therapeutics

SRPT

Attention (50-day avg)0.01%

Attention rank (50-day avg)#597

Bullish sentiment (50-day avg)83%

Price to earnings ratio45.5

Market capitalization2B

Earnings per share-1.57

Dividend yield (TTM)—

Revenue (annual)2.2B

Net income (annual)-713.4M

Social

What share of all stock conversation is about SRPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0	0.01% 0	0.01% -0.04

Sep 29

The WS analyst put $SRPT underperform, possibly due to a potential M&A deal, but the stock has shown resilience.
The $SRPT conference is scheduled for Wednesday in Japan, and the daily chart shows the stock price is intact.
The author is tracking a potential "mini boner" in $SRPT, a small but significant price movement that could indicate a larger trend, similar to those seen in other biotech stocks.

Generated by AI

Sentiment

Of the messages about SRPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +14.71	79.1% -11.28	80.11% -3.61	75.79% +14.37
Bearish	50% -14.71	20.9% +11.28	19.89% +3.61	24.21% -14.37

Bullish· Sep 23

Sarepta Therapeutics, Inc. ($SRPT) is trading at a 1.6x revenue multiple and has $475M in repurchase authorization, suggesting potential for strategic buying.
The company is on the verge of releasing a new product, WMS, which is expected to have a significant impact on its business.
$SRPT remains an interesting rare disease name to watch, with DMD (duchenne muscular dystrophy) being a space where companies building real treatment options still matter a lot.

Bearish· Sep 23

The stock's price has dropped drastically, with some users describing it as "extremely drastic" and "pathetic."
Many users are disappointed with the stock's performance, with some stating they've lost millions due to the opportunity cost and others expressing frustration with the lack of movement in the share price.
The stock's volume is low, which some users see as a positive sign, but others are concerned about the potential for a more significant drop if volume increases.

Generated by AI

Topics

Of the messages about SRPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	60.47%	53.57%	7.48%
Technical Analysis	100%	13.95%	20.98%	3.51%
Analysts	0%	0%	0.45%	35.28%
Earnings	0%	0%	6.25%	9.75%
Controversies	0%	25.58%	18.75%	1.18%
Macro	0%	0%	0%	42.8%

Earnings· May 6

Sarepta Therapeutics (SRPT) reported Q1 2026 earnings, beating estimates with revenue of $730.8M and adjusted EPS of $3.16.
The company reiterated its FY 2026 guidance for total net product revenues of $1.2-$1.4B and combined non-GAAP R&D and SG&A expenses of $800.0-$900M.
SRPT's Q1 2026 earnings were boosted by a one-time collaboration payment of $325.0 million from Roche, which was recognized in February 2026.

Analysts· Nov 5

Mizuho upgraded SRPT to Outperform with a target price of $26, citing strong Q3 demand for Elevidys and growing confidence in adoption despite earlier safety concerns.
Mizuho raised its Elevidys revenue forecasts to $725 million in 2026 and $975 million in 2031, driven by strong demand and favorable insurance coverage.
Analysts see favorable risk/reward and continued positive coverage momentum for SRPT, with Wells Fargo maintaining an Overweight rating and target price of $45.

Announcements· Mar 26

Sarepta Therapeutics, Inc. ($SRPT) shares surge over 30% after a breakthrough FDA label expansion for its gene therapy, Elevidys.
H.C. Wainwright maintains a Sell rating on $SRPT, citing early-stage siRNA muscle data that fails to offset flagship drug revenue decline.
Preliminary Phase I/II data for SRP-1001 and SRP-1003 bolsters investor confidence in $SRPT's strategic pipeline and financial runway, leading to a significant market move.

Controversies· Jul 26

The FDA is investigating the death of a patient treated with Sarepta's gene therapy Elevidys for Duchenne muscular dystrophy, citing potential safety concerns.
Sarepta's AAVrh74 platform technology designation has been revoked by the FDA due to the deaths of three children, potentially related to the company's products.
Roche, a partner of Sarepta, has stated that the recent death of a patient in Brazil who had been treated with Elevidys is unrelated to the treatment.

Technical Analysis· Mar 25

$SRPT has broken out above key resistance at $19.54 on massive volume, with momentum suggesting institutional accumulation and siRNA clinical data as the fundamental catalyst.
The confirmed breakout targets $30.80, fueled by positive siRNA clinical news, with immediate resistance sitting at $25.32, marking the prior swing high and the top of the current range.
$SRPT has decisively breached the $19.55 resistance on huge volume, with the first siRNA clinical data acting as the fundamental catalyst for this +28.62% surge, and momentum confirmed, projecting the stock towards $30.80.

Generated by AI

Community

Of the messages about SRPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	77.78%	85.5%	76.19%	83.79%
Newcomers	22.22%	14.5%	23.81%	16.21%

Regulars· Sep 25

The upcoming World Muscle Society Annual Congress (Sept. 29 - Oct. 3) will feature presentations on new data from Sarepta Therapeutics' treatments for Duchenne muscular dystrophy.
The company is expected to present updates on the EMBARK and ESSENCE trials, as well as functional and safety outcomes for ambulatory patients who were treated with delandistrogene moxeparvovec.
The siRNA platform is expected to create significant value for Sarepta Therapeutics in 2026-27, with Phase I/II MAD readouts for DM1 and FSHD representing a $1B+ opportunity each.

Newcomers· Sep 28

Many newcomers are focused on the safety and regulatory status of Sarepta's products, considering these factors more important than a potential biotech market bounce.
Some newcomers are evaluating Sarepta's cash needs and are concerned about the company's ability to move forward, despite its potential.
New investors are also considering the stock's value, with some seeing it as a good buy due to low volume and lack of news, while others are questioning the dip buyers and puking surveyors.

Generated by AI

In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

3d agoYahoo Finance

Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential

5d agoInvesting.com

Sarepta to present gene therapy data at neuromuscular meeting

5d agoInvesting.com

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie

15d agoYahoo Finance

Sarepta at Morgan Stanley conference: pipeline data and sales recovery

15d agoInvesting.com

Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ)

20d agoSeeking Alpha

Also Discussed

Investors talking about SRPT also mention

#	Name	Attention
1	BioMarin Pharmaceutical IncBMRN	0%+0
2	PTC Therapeutics, Inc.PTCT	0%new
3	Regenxbio Inc.RGNX	0%+0
4	Acadia Pharmaceuticals Inc.ACAD	0%+0
5	Alnylam Pharmaceuticals, Inc.ALNY	0%0
6	Solid Biosciences Inc.SLDB	0.16%new
7	Capricor Therapeutics, Inc.CAPR	0.35%+0.26
8	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
9	Exelixis Inc.EXEL	0%-0.03
10	uniQure N.V.QURE	0.02%+0.01

Sarepta Therapeutics, Inc.

Healthcare
Biotechnology

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders. The company develops RNA-targeted therapeutics, siRNA-based treatments, gene therapies, and other genetic medicine modalities designed to address underlying disease mechanisms. Its current portfolio includes approved and commercialized therapies for Duchenne muscular dystrophy, along with additional programs in development for other rare genetic conditions. Sarepta Therapeutics also maintains a broader research and manufacturing platform centered on advancing genetic medicine from discovery through delivery. Based in Cambridge, Massachusetts, the company plays a notable role in the rare disease market by combining therapeutic innovation with a specialized focus on patients who often have limited treatment options.

Website

Location

215 First Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about SRPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0	0.01% 0	0.01% -0.04

Sep 29

The WS analyst put $SRPT underperform, possibly due to a potential M&A deal, but the stock has shown resilience.
The $SRPT conference is scheduled for Wednesday in Japan, and the daily chart shows the stock price is intact.
The author is tracking a potential "mini boner" in $SRPT, a small but significant price movement that could indicate a larger trend, similar to those seen in other biotech stocks.

Generated by AI

Sentiment

Of the messages about SRPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +14.71	79.1% -11.28	80.11% -3.61	75.79% +14.37
Bearish	50% -14.71	20.9% +11.28	19.89% +3.61	24.21% -14.37

Bullish· Sep 23

Sarepta Therapeutics, Inc. ($SRPT) is trading at a 1.6x revenue multiple and has $475M in repurchase authorization, suggesting potential for strategic buying.
The company is on the verge of releasing a new product, WMS, which is expected to have a significant impact on its business.
$SRPT remains an interesting rare disease name to watch, with DMD (duchenne muscular dystrophy) being a space where companies building real treatment options still matter a lot.

Bearish· Sep 23

The stock's price has dropped drastically, with some users describing it as "extremely drastic" and "pathetic."
Many users are disappointed with the stock's performance, with some stating they've lost millions due to the opportunity cost and others expressing frustration with the lack of movement in the share price.
The stock's volume is low, which some users see as a positive sign, but others are concerned about the potential for a more significant drop if volume increases.

Generated by AI

Topics

Of the messages about SRPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	60.47%	53.57%	7.48%
Technical Analysis	100%	13.95%	20.98%	3.51%
Analysts	0%	0%	0.45%	35.28%
Earnings	0%	0%	6.25%	9.75%
Controversies	0%	25.58%	18.75%	1.18%
Macro	0%	0%	0%	42.8%

Earnings· May 6

Sarepta Therapeutics (SRPT) reported Q1 2026 earnings, beating estimates with revenue of $730.8M and adjusted EPS of $3.16.
The company reiterated its FY 2026 guidance for total net product revenues of $1.2-$1.4B and combined non-GAAP R&D and SG&A expenses of $800.0-$900M.
SRPT's Q1 2026 earnings were boosted by a one-time collaboration payment of $325.0 million from Roche, which was recognized in February 2026.

Analysts· Nov 5

Mizuho upgraded SRPT to Outperform with a target price of $26, citing strong Q3 demand for Elevidys and growing confidence in adoption despite earlier safety concerns.
Mizuho raised its Elevidys revenue forecasts to $725 million in 2026 and $975 million in 2031, driven by strong demand and favorable insurance coverage.
Analysts see favorable risk/reward and continued positive coverage momentum for SRPT, with Wells Fargo maintaining an Overweight rating and target price of $45.

Announcements· Mar 26

Sarepta Therapeutics, Inc. ($SRPT) shares surge over 30% after a breakthrough FDA label expansion for its gene therapy, Elevidys.
H.C. Wainwright maintains a Sell rating on $SRPT, citing early-stage siRNA muscle data that fails to offset flagship drug revenue decline.
Preliminary Phase I/II data for SRP-1001 and SRP-1003 bolsters investor confidence in $SRPT's strategic pipeline and financial runway, leading to a significant market move.

Controversies· Jul 26

The FDA is investigating the death of a patient treated with Sarepta's gene therapy Elevidys for Duchenne muscular dystrophy, citing potential safety concerns.
Sarepta's AAVrh74 platform technology designation has been revoked by the FDA due to the deaths of three children, potentially related to the company's products.
Roche, a partner of Sarepta, has stated that the recent death of a patient in Brazil who had been treated with Elevidys is unrelated to the treatment.

Technical Analysis· Mar 25

$SRPT has broken out above key resistance at $19.54 on massive volume, with momentum suggesting institutional accumulation and siRNA clinical data as the fundamental catalyst.
The confirmed breakout targets $30.80, fueled by positive siRNA clinical news, with immediate resistance sitting at $25.32, marking the prior swing high and the top of the current range.
$SRPT has decisively breached the $19.55 resistance on huge volume, with the first siRNA clinical data acting as the fundamental catalyst for this +28.62% surge, and momentum confirmed, projecting the stock towards $30.80.

Generated by AI

Community

Of the messages about SRPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	77.78%	85.5%	76.19%	83.79%
Newcomers	22.22%	14.5%	23.81%	16.21%

Regulars· Sep 25

The upcoming World Muscle Society Annual Congress (Sept. 29 - Oct. 3) will feature presentations on new data from Sarepta Therapeutics' treatments for Duchenne muscular dystrophy.
The company is expected to present updates on the EMBARK and ESSENCE trials, as well as functional and safety outcomes for ambulatory patients who were treated with delandistrogene moxeparvovec.
The siRNA platform is expected to create significant value for Sarepta Therapeutics in 2026-27, with Phase I/II MAD readouts for DM1 and FSHD representing a $1B+ opportunity each.

Newcomers· Sep 28

Many newcomers are focused on the safety and regulatory status of Sarepta's products, considering these factors more important than a potential biotech market bounce.
Some newcomers are evaluating Sarepta's cash needs and are concerned about the company's ability to move forward, despite its potential.
New investors are also considering the stock's value, with some seeing it as a good buy due to low volume and lack of news, while others are questioning the dip buyers and puking surveyors.

Generated by AI

Sarepta Therapeutics

Social

Sep 29

Bullish· Sep 23

Bearish· Sep 23

Earnings· May 6

Analysts· Nov 5

Announcements· Mar 26

Controversies· Jul 26

Technical Analysis· Mar 25

Regulars· Sep 25

Newcomers· Sep 28

Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential

Sarepta to present gene therapy data at neuromuscular meeting

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta at Morgan Stanley conference: pipeline data and sales recovery

Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ)

Also Discussed

Sarepta Therapeutics, Inc.

Company Information

Location

Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential

Sarepta to present gene therapy data at neuromuscular meeting

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta at Morgan Stanley conference: pipeline data and sales recovery

Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ)

Also Discussed

Social

Sep 29

Bullish· Sep 23

Bearish· Sep 23

Earnings· May 6

Analysts· Nov 5

Announcements· Mar 26

Controversies· Jul 26

Technical Analysis· Mar 25

Regulars· Sep 25

Newcomers· Sep 28